AVI BioPharma Reports Second Quarter Financial Results; Conference Call Begins Today at 11:00 a.m. Eastern Time.

PORTLAND, Ore. -- AVI BioPharma, Inc. (Nasdaq:AVII) today reported financial results for the three and six months ended June 30, 2006. E[acute accent]The net loss for the second quarter of 2006 was $6.9 million, or $0.13 per share, compared with a net loss for the second quarter of 2005 of $4.9 million, or $0.11 per share. Results for the second quarter of 2006 include stock-based compensation expenses of $1.0 million upon adoption of SFAS 123R. Results for the second quarter of 2005 do not include SFAS 123R compensation expenses since the adoption occurred beginning January 1, 2006. Revenues for the 2006 second quarter were $19,000, down from $39,000 in the prior-year quarter and reflecting lower grant revenues, partially offset by higher research contract revenues. E[acute accent]Research and development (R&D) expenses for the quarter increased to $5.9 million from $3.9 million last year, and general and administrative (G&A) expenses increased to $1.5 million from $1.3 million in the prior year. The increase in R&D expenses was due to an additional $650,000 in employee costs, including $640,000 related to the adoption of SFAS 123R. The increase in R&D expenses also reflects $600,000 in contracting costs for the production of GMP subunits, which are used by AVI to manufacture compounds for future clinical trials. The remaining increase in R&D expenses was due to higher clinical costs of $750,000 from the expansion of clinical programs in hepatitis C and coronary artery bypass grafting. The increase in G&A expenses was due primarily to an additional $260,000 in employee costs, including $370,000 related to the adoption of SFAS 123R, partially offset by decreases in employee costs of $130,000 when nine employees in AVI BioPharma's Colorado facility joined Cook Group Inc. (Cook) in April 2006, subsequent to AVI's licensing transaction with Cook. E[acute accent]For the six months ended June 30, 2006, AVI BioPharma reported a net loss of $16.0 million, or $0.31 per share, compared with a net loss for the comparable period in 2005 of $10.4 million, or $0.24 per share. Results for the first half of 2006 include stock-based compensation expense of $2.9 million, of which $2.1 million related to the adoption of SFAS 123R and $830,000 related to the acceleration of the vesting of certain stock options. Results for the first half of 2005 do not include SFAS 123R compensation expense. Revenues remained essentially unchanged at $85,000 for the first half of 2006 and of 2005. E[acute accent]R&D expenses for the first six months of 2006 increased to $12.7 million from $8.1 million in the prior-year period, and G&A expenses increased to $4.3 million from $2.7 million. The increase in R&D expenses was due primarily to an additional $1.7 million in employee costs, including $1.2 million related to the adoption of SFAS 123R and $430,000 related to the acceleration of the vesting of certain stock options. The R&D increase was also due to higher clinical costs of $950,000 from the expansion of clinical programs in hepatitis C and coronary artery bypass grafting. The increase in R&D expenses also reflects $500,000 in AVI common stock issued to Chiron Corporation as the first milestone payment under a license agreement granting AVI a nonexclusive license to Chiron's patents and patent applications for the research, development and commercialization of antisense therapeutics against hepatitis C virus (HCV), and $1.0 million in contracting costs for the production of GMP subunits. The remaining increase in R&D expenses was due to additional professional consulting costs of $320,000. The increase in G&A expenses was due primarily to an additional $1.5 million in employee costs, including $930,000 related to the adoption of SFAS 123R and $400,000 related to the acceleration of the vesting of certain stock options. E[acute accent]AVI BioPharma had cash, cash equivalents and short-term securities of $44.5 million as of June 30, 2006, a decrease of $2.6 million from December 31, 2005. This decrease was due primarily to $9.9 million used in operations and approximately $750,000 used for purchases of property and equipment and patent-related costs, offset by the receipt of $5.0 million in net proceeds from a stock purchase agreement with Cook Group Inc. and $3.1 million from the exercise of warrants and options and sales under the company's employee stock purchase plan during the first half of 2006. E[acute accent]In January 2006 AVI announced that the final version of the 2006 defense appropriations act had been approved, which included an allocation of $11.0 million to fund AVI's ongoing defense-related programs. AVI's NEUGENE(R) technology will be used to continue developing therapeutic agents against Ebola, Marburg and dengue viruses, as well as to continue developing countermeasures for anthrax exposure and antidotes for ricin toxin. AVI continues to work with the government to define the scope of the work to be performed on these programs. This additional funding for 2006 has not been received and has not been reflected in AVI's 2006 second quarter financial statements. E[acute accent]"Based on data reported in May from the first HCV patients treated for 14 days with our NEUGENE antisense compound AVI-4065, the clinical trial protocol was modified to extend the dosing period to enhance the pharmacokinetics and to potentially enhance viral and clinical responses. We are currently enrolling HCV patients in a 28-day treatment group with AVI-4065 under this modified protocol," said Denis R. Burger, Ph.D., chief executive officer of AVI BioPharma. "We expect to report the full set of pharmacokinetic, clinical and viral response data for the original 14-day treatment groups by the end of the third quarter. E[acute accent]"The remainder of 2006 promises to be quite active," Dr. Burger added. "We are preparing to initiate a clinical trial in coronary artery bypass grafting using Resten-CP, or AVI-5126. With the assistance of one or more pharmaceutical companies, we are preparing to enter the clinic with our Exon Skipping Pre-RNA Interference Technology, or ESPRIT, therapeutics in Duchenne muscular dystrophy. Additionally, based on strong preclinical data that indicated the ability of our NEUGENE compounds to target multiple strains of influenza, we are completing the necessary animal studies required to file an Investigational New Drug (IND) application for the treatment of avian influenza."

E[acute accent]Product Pipeline Update

E[acute accent]Technology Overview

E[acute accent]AVI has developed proprietary third-generation NEUGENE antisense technology, which is characterized by a novel synthetic backbone. NEUGENE antisense compounds are designed to bind to specific disease-causing gene sequences to disable or inactivate the disease process. AVI believes that this chemistry allows NEUGENE antisense agents to be more stable, specific, efficacious and safer than second-generation antisense compounds in clinical development by others. E[acute accent]AVI's clinical development is focused on two disease categories: cardiovascular disease and infectious disease. In addition, AVI applies its technology to certain other clinical applications that it believes are particularly amenable to antisense drug development, namely genetic disorders, inflammatory diseases and oncology. E[acute accent]In September 2005 the company announced a new application of its proprietary NEUGENE technology, called ESPRIT (Exon Skipping Pre-RNA Interference Technology). ESPRIT therapeutics allow for fine genetic surgery at the RNA processing level that enables the deletion of disease-causing genetic sequences or the skipping of functional sequences that are over-expressed or harmful in certain diseases. In February 2006 the company announced publication of an article in Nature Medicine indicating that AVI's ESPRIT technology may hold significant potential to bypass faulty dystrophin gene expression in patients with muscular dystrophy. The company is applying the ESPRIT therapeutic approach in genetic disorders, including a potential collaborative program in muscular dystrophy, as well as to diseases with an immunologic component, such as diabetes and multiple sclerosis.

E[acute accent]Cardiovascular Disease Program

E[acute accent]Resten-NG(R) (AVI-4126) is a NEUGENE antisense drug for treating cardiovascular restenosis, the re-narrowing of a coronary artery following angioplasty. Resten-NG inhibits the expression of the c-myc gene, which plays a key role in the development of the pathology leading to restenosis. In a completed Phase II study, AVI demonstrated that Resten-NG prevented restenosis at the site of balloon angioplasty as measured by angiography and intravascular ultrasound at six months. In March 2006 AVI announced a development and commercialization agreement with Cook Group Inc., in which Cook licensed AVI-4126 for the down-regulation of c-myc gene expression in vascular diseases. This agreement covers device-delivery of Resten-NG as well as Resten-MP(TM), the microparticle formulation of AVI-4126, for treating cardiovascular restenosis. As part of this agreement, Cook has assumed control of the ongoing APPRAISAL Phase II clinical study, in which Resten-MP is being evaluated in the prevention of cardiovascular restenosis when delivered intravenously in conjunction with the placement of one or more bare-metal stents. In preclinical studies Resten-MP was as effective in preventing cardiovascular restenosis as was AVI-4126 delivered by catheters or stents. E[acute accent]AVI has finished preclinical studies with Resten-CP (AVI-5126) for coronary artery bypass grafting (CABG). This drug is AVI-4126 with transporter tail (CytoPorter(TM), CP) attached to enhance delivery to the saphenous vein ex vivo before use in bypass surgery. Based on positive results from both animal studies and Phase II clinical results with NEUGENE antisense targeting c-myc for restenosis, AVI is moving into clinical trials in CABG later this year.

E[acute accent]Infectious Disease Program

E[acute accent]AVI's infectious disease program is extensive, and encompasses research on more than 50 different viruses representing most viral families, and involves collaborations with investigators worldwide. Results from these studies have enhanced AVI's ability to design effective agents for emerging as well as for engineered pathogens. AVI's antiviral research program has produced antisense drugs shown to be active in preclinical studies against a wide range of RNA viruses, including HCV, influenza A virus, West Nile virus, dengue virus, SARS coronavirus, Ebola virus and Marburg virus. AVI has confirmation through independent laboratories of NEUGENE antisense efficacy in preclinical experiments against multiple strains of influenza, including avian influenza strain H5N1, a potential worldwide public health threat. E[acute accent]AVI plans to focus its antiviral drug development program on infectious diseases that represent large market opportunities. The company announced in June 2005 the acceptance of an IND application by the U.S. Food and Drug Administration (FDA) for the treatment of HCV using the company's NEUGENE compound AVI-4065. In September 2005 AVI announced the initiation of an HCV clinical trial to assess the safety, tolerability, pharmacokinetics and viral response to treatment with AVI-4065 in healthy volunteers and patients with chronic active HCV. The company reported favorable safety, tolerability and pharmacokinetic results in January 2006 from the first phase of its HCV program. Based on preliminary data in the second phase of the HCV study presented in May 2006, the clinical trial protocol was modified to allow for extended treatment duration with AVI-4065 to enhance the pharmacokinetics and potentially enhance viral and clinical response in HCV patients. In July 2006 AVI began patient enrollment to fill an extended treatment cohort in this study. AVI expects to announce results of patients included in the original HCV treatment protocol by the end of the 2006 third quarter. E[acute accent]To potentially address the large seasonal influenza commercial market, AVI has developed NEUGENE antisense drug candidates that target genetic regions of the influenza A virus that are highly conserved between the six viral subtypes that cause human disease. These include three subtypes that caused pandemics in the 20th century -- the 1918 Spanish flu (H1N1), the 1957 Asian flu (H2N2) and the 1968 Hong Kong flu (H3N2) -- and three subtypes of avian flu that have been reported to cause disease in humans (H5N1, H7N7 and H9N2). Collaborators have confirmed that a single NEUGENE drug was effective in preclinical studies against most influenza subtypes, including the emerging H5N1 avian strain. AVI plans to file an IND application later this year for its NEUGENE drug for avian flu that is also efficacious against the far more common influenza A viruses, which kill an average of 35,000 Americans every year. E[acute accent]The company is collaborating with the Centers for Disease Control and Prevention (CDC) in its dengue virus program, and expects dengue fever/dengue hemorrhagic fever to be the next viral program to move into clinical development.

E[acute accent]Bio-Defense Program

E[acute accent]AVI has an active collaborative program with the Department of Defense in the area of bio-threats and emerging diseases. In 2005 and early 2006 AVI received $4.6 million for ongoing programs in drug development for the highly lethal Ebola and Marburg viruses, and countermeasures for ricin and anthrax toxins. In January 2006 the final version of the 2006 defense appropriations act was approved, which included an allocation of $11.0 million to fund AVI's ongoing defense-related programs. AVI continues to work with the government to define the scope of the work to be performed on these programs. This additional funding has not been received and has not been reflected in AVI's 2006 second quarter financial statements.

E[acute accent]Conference Call

E[acute accent]AVI BioPharma has scheduled an investor conference call regarding this announcement, and the company's current and planned business activities, to be held today beginning at 11:00 a.m. Eastern time. E[acute accent]Individuals interested in listening to the conference call may do so by dialing [phone] within the U.S. and Canada, or [phone] for international callers. A telephone replay of the conference call will be available for 48 hours beginning within two hours of the conclusion of the call, by dialing [phone] for domestic callers, or [phone] for international callers, and entering reservation number 3161072. E[acute accent]The live conference call also will be available to private investors via the Internet at www.avibio.com. A replay of the call will be available on the company's Web site for 14 days following the completion of the call.

E[acute accent]About AVI BioPharma

E[acute accent]AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis, cancer and polycystic kidney disease. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, Ebola virus and influenza A virus. AVI has introduced a NEUGENE-based exon-skipping technology called ESPRIT therapy. More information about AVI is available on the company's Web site at http://www.avibio.com.

E[acute accent]"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.

AVI BioPharma, Inc.
                     (A Development-Stage Company)
                       STATEMENTS OF OPERATIONS
                              (unaudited)


                    Three Months Ended          Six Months Ended
                         June 30,                   June 30,
                  ------------------------  --------------------------
                     2006         2005         2006          2005
                  -----------  -----------  ------------  ------------
Revenues, from
 license fees,
 grants and
 research
 contracts       $    18,558  $    39,317  $     84,520  $     84,509
Operating
 expenses:
  Research and
   development     5,921,929    3,915,155    12,685,174     8,057,059
  General and
   administrative  1,515,711    1,272,529     4,337,437     2,721,059
                  -----------  -----------  ------------  ------------
                   7,437,640    5,187,684    17,022,611    10,778,118

Other income:
   Interest
    income, net      517,053      215,725       974,912       261,788
                  -----------  -----------  ------------  ------------
Net loss         $(6,902,029) $(4,932,642) $(15,963,179) $(10,431,821)
                  ===========  ===========  ============  ============
Net loss per
 share--
  basic and
  diluted        $     (0.13) $     (0.11) $      (0.31) $      (0.24)
                  ===========  ===========  ============  ============
Shares used in
 per share
 calculations     52,946,054   44,167,565    52,333,952    43,316,268
                  ===========  ===========  ============  ============


                       BALANCE SHEET HIGHLIGHTS
                              (unaudited)


                                         June 30,         December 31,
                                           2006              2005
                                       -------------     -------------
Cash, cash equivalents and
 short-term securities                $  44,473,487     $  47,051,082
Total current assets                     45,101,376        48,653,394
Total assets                             52,384,016        56,407,982
Total current liabilities                 2,264,821         2,747,973
Total shareholders' equity            $  50,119,195     $  53,660,009